Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago. These figures are ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Accolade Inc (NASDAQ:ACCD) stands against the ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Accolade, Inc. (NASDAQ:ACCD) stands against the other smid-cap ...

A downtrend has been apparent in Accolade (ACCD) lately with too much selling pressure. The stock has declined 15.6% over the past four weeks. However, given the fact that it is now in oversold ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to ...

ACCD's revenue growth is projected to decelerate in FY 2025; the company's top line outlook for the new fiscal year remains weak, considering the latest staff redundancy numbers and the company's ...